# CJC-1295 Medicine

> An unrolled scroll of what the medical literature actually says about CJC-1295 — the GHRH analog, the DAC variant, the discontinued clinical program.

## Pages

- [Overview](https://cjc1295medicine.com/index.md): CJC-1295 is a 30-residue GHRH analog whose DAC variant produced 2- to 10-fold GH elevations for six days in healthy adults. An editorial scroll of the published medical literature.
- [Research](https://cjc1295medicine.com/research.md): What the published research on CJC-1295 shows: GHRH receptor agonism, Gαs/cAMP signaling, pulsatile GH amplification, and the difference between CJC-1295 DAC and CJC-1295 no DAC.
- [Dosage](https://cjc1295medicine.com/dosage.md): CJC-1295 dosage in the published medical literature: Teichman 2006 used ascending subcutaneous doses of 30, 60, 125, and 250 mcg/kg in healthy adults. A research-context summary.
- [Side effects](https://cjc1295medicine.com/side-effects.md): CJC-1295 side effects logged in published Phase 1 and Phase 2 trials: injection-site reactions, transient flushing, headache, and class-level GH-axis edema. An editorial digest.
- [FAQ](https://cjc1295medicine.com/faq.md): Plain-English answers to the most common questions about CJC-1295: half-life, DAC vs no-DAC, doses studied in clinical trials, side effects, FDA status, and developmental history.
- [References](https://cjc1295medicine.com/references.md): Full reference list for the editorial scroll on CJC-1295: peer-reviewed primary literature (Teichman 2006, Jetté 2005), analytical and regulatory sources, with DOIs and PubMed URLs.
- [About](https://cjc1295medicine.com/about.md): About CJC-1295 Medicine — an independent editorial project that publishes plain-English summaries of the peer-reviewed CJC-1295 research literature. Not a clinic, not a vendor.
- [Contact](https://cjc1295medicine.com/contact.md): Contact the editorial desk of CJC-1295 Medicine. We are an independent editorial scroll of the CJC-1295 literature — not a clinic, not a vendor. For corrections and reading questions only.